Regenxbio Launches Pivotal Phase of Affinity Duchenne Trial for RGX-202 Gene Therapy with Positive Functional Results
Regenxbio Launches Pivotal Phase of Affinity Duchenne Trial for RGX-202 Gene Therapy with Positive Functional Results Description: Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026. Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with the first patient dosed. Phase I/II data…